Targeting the Recalcitrance of Cancer



Alanis is developing precision antibodies for the treatment of cancers that are resistant to current treatments

Precision medicine is the future of cancer therapy

Current paradigm for the treatment of AML:

- Targets clonal genetic variants arising from the bone marrow stroma
- Fails to eliminate residual leukemic stem cells

Our approach targets:

- Malignant stem cells in the bone marrow
- Minimum residual disease to improve overall survival



Bone marrow microenvironment supports residual disease leading to relapse

There is significant unmet need and opportunity in MDS/AML for therapy targeting residual disease to improve survival

The AML global drug market in 2024 is ~$3B USD and is estimated to reach over $6.5B by 2030

The MDS global drug market in 2024 is ~$2B and is expected to double to >$4B by 2030

Growth will be driven by population aging, earlier detection, and new disease-modifying drugs

[Grand View Research 2024 Report ID: GVR-2-68038-434-5 & GVR-4-68040-384-0]

Targeting Jagged-1/Notch-1: The pathway in the bone marrow driving leukemogenesis in MDS/AML

β-catenin & jagged-1 expression are elevated in osteoblasts by FOX01 increasing Notch1 signaling in leukemic stem cells

β-cat/Jagged-1^{+} osteoblasts are hijacked to drive leukemogenesis via elevated Notch1 signaling, undermining normal hematopoiesis

Cytokine-mediated LSC feedback loop maintains aberrant osteoblast-based signaling

Disease progression increases osteoblast and LSC nests, depleting marrow, raising Jagged-1^{+} osteoblasts, worsening anemia and elevating blast counts

Notch1 signaling between osteoblasts and leukemic stem cells



[Kode et al. Leukemia 2016 January ; 30(1): 1–13]

The oncogenic signaling pathway is detected in up to 70% of high-risk MDS/AML patients

- >450 patient samples analyzed
- Samples were tested across the different disease classifications
- Normal subjects ≤ 5% β-catenin activation



[Mosialou et al., Cancer Cell: 43:1007 2025]

Treatment of ex vivo bone marrow cultures from Notch1–activated MDS/AML patients with the antibody to jagged-1 ATI-D1

- Inhibits tumor cell proliferation
- Promotes tumor cell death
- Restores hematopoiesis

Metric	Change	Disease
Proliferating Cells	0%	$Healthy^{Low}$
Proliferating Tumor Cells	↓60-100% in 86% patients	MDS^{Low}/MDS^{High}
Dead Tumor Cells	↑50-100% in 50% patients	MDS^{Low}/MDS^{High}
Myeloid Cells	↑110%	AML^{Low}/AML^{High}
Erythroid Cells	↑100%	AML^{Low}/AML^{High}

[Mosialou et al., Cancer Cell: 43:1007 2025]

Alanis Therapeutics INC

Treatment of AML mice with ATI-D1

- Restores weight gain
- Restores hematopoiesis
- Prolongs survival







Treatment restores hematologic status

Status	Wild type mice		AML mice	
Treatment	Control IgG	ATI-D1	Control IgG	ATI-D1
Anemia (RBC account)	Normal	Normal	<50% Normal	Normal
Thrombocytopenia	Normal	Normal	<50% Normal	Normal
WBC count	Normal	Normal	<50% Normal	Normal
Lymphocytes	Normal	Normal	<50% Normal	Normal
Neutrophils	Normal	Normal	<50% Normal	Normal

[Mosialou et al., Cancer Cell: 43:1007 2025]

Alanis Therapeutics INC

ATI-D1 Development Status

- Antibody Master Cell Bank created (yield>8.0g/L)
- Scale up, analytical methods, process development ongoing
- pIND 1Q 2026
- Phase 1/2 trial in high risk MDS and AML with biomarker planned

Alanis can reach clinical proof of concept in 3 years

Intellectual property

- Issued patent covering the jagged-1 target
- ATI-D1 Composition of matter patent pending

Fundraising & timeline

Open to licensing especially co-development
Seeking $10M in a Series A to support development over the next ~2-3 years to

- Match a $4.5M NCI Phase IIb Development Award
- Complete IND and generate cGMP antibody
- Complete a Phase 1/2 clinical trial in MDS/AML

Alanis has received $3M in funding to date

An exceptional team of experts with the experience and knowledge to support the efforts…

Executive Team

Bob Goodenow Ph.D
CEO/BOD

Danelle James M.D.
CMO



Catherine Woods Ph.D.
R&D

Elizabeth Song Ph.D.
Operations/Essorant

Jill Herendeen D. Pharm
Regulatory /Rubicon

Board of Directors and Advisors

Bob Goodenow Ph.D
CEO/BOD

Xiaomin Fan Ph.D.
BOD/CEO AvantGen

Cindy Collins
BOD/CEO Nutcracker

Stavroula Kousteni Ph.D.
Columbia University

Azra Raza, M.D.
Columbia University

Alanis Therapeutics INC

For more information please contact

Bob Goodenow CEO

Robert.Goodenow@alanistx.com

www.https://alanistx.com



Precision medicine is the future of cancer therapy